Non-MALT marginal zone lymphomas

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Thieblemont, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PENTOSTATIN; PURINE DERIVATIVE; RIBAVIRIN; RITUXIMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BETA 2 MICROGLOBULIN; DRUG DERIVATIVE; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; VIDARABINE;

B CELL LYMPHOMA; BONE MARROW EXAMINATION; CANCER GROWTH; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; NODULAR LYMPHOMATOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SPLEEN TUMOR; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; CLASSIFICATION; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; GENETICS; ITALY; LYMPH NODE; LYMPHOCYTOSIS; MALE; MIDDLE AGED; PATHOLOGY; SURVIVAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITALY; L-LACTATE DEHYDROGENASE; LYMPH NODES; LYMPHOCYTOSIS; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PROGNOSIS; SPLENECTOMY; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; VIDARABINE;

EID: 48149103434     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn202     Document Type: Review

References (46)

1. Maclennan IC. B cells: The follicular dimension of the marginal zone. Immunol Cell Biol 2008; 86: 219-220.
2. MacLennan IC, Liu YJ, Oldfield S, Zhang J, Lane PJ. The evolution of B-cell clones. Curr Top Microbiol Immunol 1990; 159: 37-63.
3. Harris NL, Jaffe ES, Stein H et al. A revised European-American Classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2001.
5. Kimby E, Treon SP, Anagnostopoulos A et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6: 380-383.
6. Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood 2006; 107: 3442-3446.
7. Traverse-Glehen A, Baseggio L, Callet-Bauchu E et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: A distinct clinicopathologic and molecular entity? Blood 2008; 111: 2253-2260.
8. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 41-46.
9. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes. Natural history and response to therapy in 50 cases. Br J Haematol 1991; 78: 206-209.
10. Troussard X, Valensi F, Duchayne E et al. Splenic lymphoma with villous lymphocytes: Clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996; 93: 731-736.
11. Thieblemont C, Felman P, Callet-Bauchu E et al. Splenic marginal-zone lymphoma: A distinct clinical and pathological entity. Lancet Oncol 2003; 4: 95-103.
12. Nathwani B, Anderson J, Armitage J et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999; 17: 2486-2492.
13. Berger F, Felman P, Thieblemont C et al. Non-MALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
14. Chacón J, Mollejo M, Muñoz E et al. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
15. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: A report on 129 patients. Br J Haematol 2003; 120: 759-764.
16. Arcaini L, Lazzarino M, Colombo N et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107: 4643-4649.
17. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 2003; 88: 80-93.
18. Talamini R, Montella M, Crovatto M et al. Non-Hodgkin's lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. Int J Cancer 2004; 110: 380-385.
19. Arcaini L, Burcheri S, Rossi A et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007; 18: 346-350.
20. Arcaini L, Paulli M, Boveri E et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107-115.
21. Seve P, Renaudier P, Sasco AJ et al. Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: A cross-sectional study in Lyon, France. Eur J Gastroenterol Hepatol 2004; 16: 1361-1365.
22. Thieblemont C, Felman P, Berger F et al. Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients. Clin Lymphoma 2002; 3: 41-47.
23. Iannitto E, Ambrosetti A, Ammatuna E et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004; 101: 2050-2057.
24. Hermine O, Lefrere F, Bronowicki J et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 11: 89-94.
25. Matutes E, Oscier D, Montalban C et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22: 487-495.
26. Ruiz-Ballesteros E, Mollejo M, Rodriguez A et al. Splenic marginal zone lymphoma: Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106: 1831-1838.
27. Thieblemont C, Nasser V, Felman P et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004; 103: 2727-2737.
28. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martínez P, Piris M. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia 2007; 21: 2547-2549.
29. Novara F, Arcaini L, Merli M et al. High resolution array-CGH in splenic marginal zone B-cell lymphoma: Correlation of copy number imbalances with HCV status and prognostic categories. Blood 2007: 110 (Abstr 2620).
30. Hockley S, Giannouli S, Morilla A, Morgan G, Matutes E, Gonzalez D. Different IGH rearrangement and somatic hypermutation patterns in hairy-cell leukemia, hairy-cell leukemia variant and splenic marginal zone lymphoma. Blood 2007: 110 (Abstr 2082).
31. Chacon J, Mollejo M, Munoz E et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
32. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999; 36: 148-154.
33. Franco V, Florena A, Stella M et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001; 91: 294-301.
34. Lefrere F, Hermine O, Belanger C et al. Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573-575.
35. Lefrere F, Hermine O, Francois S et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40: 113-117.
36. Iannitto E, Luminari S, Mammi C et al. Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL). A GISL study. Blood 2007: 110 (Abstr 1293).
37. Camacho FI, Mollejo M, Mateo MS et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma - A description of a series of 12 cases. Am J Surg Pathol 2001; 25: 1268-1276.
38. Neubauer A, Thiede C, Morgner A et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89: 1350-1355.
39. Arcaini L, Paulli M, Boveri E et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107-115.
40. Camacho FI, Algara P, Mollejo M et al. Nodal marginal zone lymphoma: A heterogeneous tumor: A comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003; 27: 762-771.
41. Oh SY, Ryoo BY, Kim WS et al. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006; 85: 781-786.
42. Berger F. The different entities and diagnostic problems. Educational Program of the European Hematology Association Meeting 2000: 5.
43. Dierlamm J, Pittaluga S, Wlodarska I et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996; 87: 299-307.
44. Dierlamm J, Rosenberg C, Stul M et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia 1997; 11: 747-758.
45. Slovak ML, Weiss LM, Nathwani BN, Bernstein L, Levine AM. Cytogenetic studies of composite lymphomas: Monocytoid B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Hum Pathol 1993; 24: 1086-1094.
46. Koh L, Lim L, Thng C. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 2000; 17: 225-228.